Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
The Lancet. Respiratory Medicine|July 22, 2019
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled studyToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Respiratory Medicine|May 20, 2014
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosisLuca Richeldi, Vincent Cottin, Kevin R Flaherty, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|January 9, 2021
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trialImre Noth, Vincent Cottin, Nazia Chaudhuri, et al.
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
The European Respiratory Journal|August 30, 2022
Nintedanib in children and adolescents with fibrosing interstitial lung diseasesRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
The Lancet. Respiratory Medicine|July 22, 2019
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled studyToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Respiratory Medicine|May 20, 2014
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosisLuca Richeldi, Vincent Cottin, Kevin R Flaherty, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|January 9, 2021
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trialImre Noth, Vincent Cottin, Nazia Chaudhuri, et al.
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
The European Respiratory Journal|August 30, 2022
Nintedanib in children and adolescents with fibrosing interstitial lung diseasesRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Pageof 7